Core Insights - BioSyent Inc. reported strong financial results for Q3 and YTD 2025, with total company sales increasing by 28% in Q3 and 27% year-to-date, driven by growth in both Canadian and international pharmaceutical sales [1][2] Financial Performance - Canadian Pharma Sales reached CAD 9,864,254 in Q3 2025, a 19% increase compared to Q3 2024, and CAD 28,351,130 year-to-date, up 16% [1] - International Pharma Sales surged to CAD 1,153,742 in Q3 2025, a remarkable 94% increase year-over-year, and CAD 3,134,572 year-to-date, reflecting a 316% growth [1] - Legacy Business Sales also saw significant growth, with Q3 2025 sales of CAD 1,203,808, an 83% increase, and year-to-date sales of CAD 1,894,358, up 73% [1] - Total Company Sales for Q3 2025 were CAD 12,221,804, a 28% increase, and CAD 33,380,060 year-to-date, a 27% increase [1][7] - EBITDA for Q3 2025 was CAD 3,632,399, a 27% increase, with a consistent EBITDA margin of 30% [1][7] - Net Income After Taxes (NIAT) for Q3 2025 was CAD 2,682,340, a 16% increase, and CAD 7,020,444 year-to-date, up 24% [1][7] Business Highlights - The company’s products, FeraMAX® and Tibella® / Tibelia®, continue to show profitable sales growth both domestically and internationally [2] - The acquisition of worldwide rights to Tibella® / Tibelia® in September 2024 has met initial expectations for sales and profit growth [2] Shareholder Information - BioSyent has declared a quarterly cash dividend of CAD 0.05 per common share, with the next payment scheduled for December 15, 2025 [5] - The company repurchased 19,500 common shares under a Normal Course Issuer Bid (NCIB) during YTD 2025 [5] - As of September 30, 2025, the company had 11,262,282 common shares outstanding [6] Balance Sheet Overview - Total assets as of September 30, 2025, were CAD 47,785,381, a 16% increase from CAD 41,359,450 at the end of 2024 [9] - Current assets increased by 47% to CAD 35,969,294, driven by a significant rise in trade and other receivables [9] - Total equity rose by 14% to CAD 39,902,869, reflecting the company's strong financial position [9]